Change of previously communicated allocation of the Group's interest-bearing liabilities
Recipharm AB published its interim report for January–March 2020 on May 7, 2020. In the section Condensed consolidated statement of financial position the interim report stated that the item Non-current interest-bearing liabilities amounted to SEK 13,475.3 million and the item Current interest-bearing liabilities amounted to SEK 87.3 million. The correct allocation shall be that the item Non-current interest-bearing liabilities amounts to SEK 11,475.3 million and the item Current interest-bearing liabilities amounts to SEK 2,087.3 million. The change does not affect the communicated